Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy
Thomas J. Povsic, Mauricio G. Cohen(Santa Ana College), Roxana Mehran(Mount Sinai Hospital), Christopher E. Buller(Teleflex (United States)), J. Krasnow, Steven L. Zelenkofske(Novartis (Switzerland)), Merrill Krolick(Heart & Vascular Institute of Florida), William A. Wargin(Ottawa Hospital), John H. Alexander(Ohio State University Hospital), Christopher P. Rusconi(University of North Carolina at Chapel Hill), Richard C. Becker(Clinical Research Institute), Christoph Bode(University Medical Center Freiburg)
Cited by 43
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Circulation|2011|3.3k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k